Turtle Cameron's Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed Jul 2, 2026
- Accession no.
- 0001636282-26-000086
- Filed
- Jul 2, 2026, 9:32 PM ET
- Trade date
- Jul 1, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.32M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Turtle CameronCIK 0001758363 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Common Stock | SSaleDisposed | −10,176 | $87.44 | −$889,789.44 | 587,364 | Direct | |
| Jul 1, 2026 | Common Stock | SSaleDisposed | −4,234 | $88.12 | −$373,100.08 | 583,130 | Direct | |
| Jul 1, 2026 | Common Stock | SSaleDisposed | −590 | $88.91 | −$52,456.9 | 582,540 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.